SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunex
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael Yang who started this subject12/3/2001 10:45:12 AM
From: eric ross  Read Replies (1) of 656
 
UBS Geoffrey Harris downgraded IMNX due to valuation, yet, most of his other biotech recommendations had no earnings to show. Perhaps, this guy is accumulating shares in anticipation of January's FDA's approval for ENBREL, which he will upgrade later on. Once again, IMNX is in a very stable position at this level, much more so since most of the acquisition by major institution occurred at the price level of 24-26 per share.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News